NASDAQ:CAI Caris Life Sciences (CAI) Stock Price, News & Analysis $31.11 +0.40 (+1.30%) Closing price 04:00 PM EasternExtended Trading$31.44 +0.33 (+1.05%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Caris Life Sciences Stock (NASDAQ:CAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Caris Life Sciences alerts:Sign Up Key Stats Today's Range$30.10▼$31.5650-Day Range$20.97▼$32.2752-Week Range$14.19▼$33.13Volume3.54 million shsAverage Volume4.11 million shsMarket Capitalization$8.79 billionP/E Ratio85.31Dividend YieldN/APrice Target$28.55Consensus RatingModerate Buy Company Overview Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies. Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools. Caris also provides pharmaceutical and biotechnology companies with molecular data, research services and clinical-trial support intended to aid biomarker discovery, patient identification and the development of targeted cancer treatments. Founded in 2008, Caris is headquartered in Irving, Texas, and serves oncologists, health systems, researchers and biopharmaceutical companies. Its operations and testing services support customers in the United States and international markets. Founder David D. Halbert serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More Caris Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreCAI MarketRank™: 2.742579528815 of 5 starsCaris Life Sciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 442nd out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingCaris Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 8 buy ratings, 5 hold ratings, and 1 sell rating.Downside RiskCaris Life Sciences has a consensus price target of $28.55, representing about 8.2% downside from its current price of $31.11.Amount of Analyst CoverageCaris Life Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Caris Life Sciences' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth230.77% Earnings GrowthEarnings for Caris Life Sciences are expected to grow by 230.77% in the coming year, from $0.13 to $0.43 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Caris Life Sciences is 85.31, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.74.Price to Earnings Ratio vs. SectorThe P/E ratio of Caris Life Sciences is 85.31, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.74.Price to Book Value per Share RatioCaris Life Sciences has a P/B Ratio of 15.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.83% of the float of Caris Life Sciences has been sold short.Short Interest Ratio / Days to CoverCaris Life Sciences has a short interest ratio ("days to cover") of 2.48, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Caris Life Sciences has recently increased by 4.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCaris Life Sciences does not currently pay a dividend.Dividend GrowthCaris Life Sciences does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.57 News SentimentCaris Life Sciences has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Caris Life Sciences this week, compared to 4 articles on an average week.Search InterestOnly 5 people have searched for CAI on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows3 people have added Caris Life Sciences to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Caris Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,205,419.00 in company stock.Percentage Held by Insiders50.00% of the stock of Caris Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCaris Life Sciences has minimal institutional ownership at this time.Read more about Caris Life Sciences' insider trading history. Receive CAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Caris Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAI Stock News HeadlinesCaris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer DetectionOctober 19 at 6:30 AM | prnewswire.comCaris Life Sciences (NASDAQ:CAI) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst SaysOctober 16, 2026 | americanbankingnews.comLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.October 20 at 1:00 AM | Profits Run (Ad)Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026October 15, 2026 | prnewswire.comCaris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026October 14, 2026 | prnewswire.comBofA Securities Adjusts Caris Life Sciences Price Target to $35 From $23October 9, 2026 | marketscreener.comMConsensus price target for Caris Life Sciences decreased by 13.14% to MX$311.55October 6, 2026 | msn.comCaris Life Sciences (NASDAQ:CAI) Insider Sells $238,650.00 in StockSeptember 24, 2026 | insidertrades.comSee More Headlines CAI Stock Analysis - Frequently Asked Questions How have CAI shares performed this year? Caris Life Sciences' stock was trading at $26.98 on January 1st, 2026. Since then, CAI shares have increased by 15.3% and is now trading at $31.11. How were Caris Life Sciences' earnings last quarter? Caris Life Sciences, Inc. (NASDAQ:CAI) released its quarterly earnings data on Thursday, February, 26th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.01 by $0.27. The company's revenue was up 125.4% compared to the same quarter last year. Read the conference call transcript. Is Caris Life Sciences doing a stock buyback? Caris Life Sciences' Board of Directors approved a share repurchase plan on Monday, June 8th 2026, which authorizes the company to repurchase $100,000,000 in shares, according to EventVestor. This means that the company could purchase up to 2.2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company's management believes its stock is undervalued. When did Caris Life Sciences IPO? Caris Life Sciences (CAI) raised $459 million in an initial public offering (IPO) on Wednesday, June 18th 2025. The company issued 23,529,412 shares at $19.00-$20.00 per share. Who are Caris Life Sciences' major shareholders? Top institutional investors of Caris Life Sciences include Zevenbergen Capital Investments LLC (0.25%), Krilogy Financial LLC (0.01%), City Center Advisors LLC (0.01%) and NorthCrest Asset Manangement LLC (0.01%). Insiders that own company stock include David Baxley Spetzler, Jon Halbert, Brian J Brille, John Russel Denton, Luke Thomas Power and Jeff L Vacirca. View institutional ownership trends. How do I buy shares of Caris Life Sciences? Shares of CAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/26/2026Today10/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CAI's financial health is in the Green zone, according to TradeSmith. CAI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:CAI CIK2019410 Webwww.carislifesciences.com Phone(866) 771-8946FaxN/AEmployees1,846Year Founded2008Price Target and Rating Average Price Target for Caris Life Sciences$28.55 High Price Target$36.00 Low Price Target$21.00 Potential Upside/Downside-8.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E Ratio85.31 Forward P/E Ratio239.31 P/E GrowthN/ANet Income-$68.09 million Net Margins10.62% Pretax Margin10.61% Return on Equity18.77% Return on Assets9.34% Debt Debt-to-Equity Ratio0.66 Current Ratio5.53 Quick Ratio4.88 Sales & Book Value Annual Sales$812.03 million Price / Sales10.83 Cash Flow$1.62 per share Price / Cash Flow19.26 Book Value$2.05 per share Price / Book15.18Miscellaneous Outstanding Shares282,600,000Free Float141,298,000Market Cap$8.79 billion OptionableOptionable Beta0.86 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:CAI) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle ...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Caris Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Caris Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
